According to a newly published market research report by 24LifeSciences, global immune checkpoint inhibitors market was valued at USD 42.6 billion in 2023 and is projected to reach USD 98.7 billion by 2032, growing at a compound annual growth rate (CAGR) of 10.7% during the forecast period 2025-2032. Immune checkpoint inhibitors are monoclonal antibodies that block proteins used by cancer cells...

The global oncology therapeutics industry is experiencing rapid advancement due to the increasing prevalence of cancer and the growing adoption of immunotherapy-based treatments. Tecentriq, an immunotherapy drug widely used in cancer treatment, has gained strong recognition for its effectiveness in managing various forms of cancer, including lung cancer and urothelial carcinoma. The increasing...